Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Biopolymers

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/bip.360370203PMID 7893947
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neural control of human airways in health and disease.

  2015cited by this paper
• Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro.

  2015cited by this paper
• Structure-activity studies of vasoactive intestinal peptide (VIP): cyclic disulfide analogs.

  2009cited by this paper
• Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cats, and human subjects

  2004cited by this paper
• Effects of vasoactive intestinal polypeptide on antigen‐induced bronchoconstriction and thromboxane release in guinea‐pig lung

  1993cited by this paper
• Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells

  1992cited by this paper
• Degradation of vasoactive intestinal peptide in bronchial alveolar lavage fluid

  1992cited by this paper
• Evolution of the growth hormone-releasing factor (GRF) family of peptides.

  1992cited by this paper
• Vasoactive intestinal polypeptide (VIP) in asthma.

  1991cited by this paper
• VIP as a modulator of lung inflammation and airway constriction.

  1991cited by this paper
• Structural determination of the vasoactive intestinal peptide by two‐dimensional 1H‐nmr spectroscopy

  1991cited by this paper
• Vasoactive intestinal polypeptide precursors have highly potent bronchodilatory activity.

  1991cited by this paper
• Structure-activity studies of vasoactive intestinal polypeptide.

  1991cited by this paper
• Vasoactive Intestinal Polypeptide (VIP) in Asthma a

  1991cited by this paper
• Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics.

  1989cited by this paper
• Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma.

  1989cited by this paper
• Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret.

  1989cited by this paper
• Amino acid preferences for specific locations at the ends of alpha helices.

  1988cited by this paper
• Synthesis and airway smooth muscle relaxant activity of linear and cyclic vasoactive intestinal peptide analogs

  1988cited by this paper
• Development of helix-based vasoactive intestinal peptide analogues: identification of residues required for receptor interaction.

  1988cited by this paper
• Helix signals in proteins.

  1988cited by this paper
• Pharmacological characterization of VIP receptors in human lung membranes.

  1988cited by this paper
• Helix stabilization by Glu-...Lys+ salt bridges in short peptides of de novo design.

  1987cited by this paper
• The effect of vasoactive intestinal peptide on smooth muscle tone and mucus secretion from the ferret trachea

  1987cited by this paper
• VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways.

  1986cited by this paper
• Vaso-active intestinal peptide: a neurotransmitter which reduces human NK cell activity and increases Ig synthesis.

  1985cited by this paper
• VIP like immunoreactive nerves in human respiratory tract

  1985cited by this paper
• Synthesis, conformational studies and biological activities of VIP and related fragments.

  1984cited by this paper
• Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma.

  1984cited by this paper
• Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide.

  1984cited by this paper
• Isolation and Amino Acid Composition of Human Vasoactive Intestinal Polypeptide (VIP)

  1982cited by this paper
• Regulatory peptides and neuron-specific enolase in the respiratory tract of man and other mammals.

  1982cited by this paper
• Studies on Peptides. XCVII. Synthesis of Porcine Glu8-Vasoactive Intestinal Polypeptide (VIP)

  1980cited by this paper
• Nerve supply to the lungs.

  1979cited by this paper
• Empirical predictions of protein conformation.

  1978cited by this paper
• A preferred conformation in the vasoactive intestinal peptide (VIP). Molecular architecture of gastrointestinal hormones

  1974cited by this paper
• Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon.

  1972cited by this paper

• The role of vasoactive intestinal peptide in pulmonary diseases.

  2023cites this paper
• Immunomodulatory Roles of PACAP and VIP: Lessons from Knockout Mice

  2018cites this paper
• Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery.

  2015cites this paper
• Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability.

  2013cites this paper
• Vasodilatory Effect of the Stable Vasoactive Intestinal Peptide Analog RO 25-1553 in Murine and Rat Lungs

  2013cites this paper
• Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics.

  2013cites this paper
• Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.

  2013cites this paper
• Nanoparticle-mediated treatment of pulmonary arterial hypertension.

  2012cites this paper
• ituitary adenylate cyclase-activating polypeptide plays an anti-inflammatory ole in endotoxin-induced airway inflammation : In vivo study with gene-deleted ice

  2011cites this paper
• Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis

  2011cites this paper
• Pituitary adenylate cyclase-activating polypeptide plays an anti-inflammatory role in endotoxin-induced airway inflammation: In vivo study with gene-deleted mice

  2011cites this paper
• Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist.

  2011cites this paper
• Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.

  2011cites this paper
• Dual bronchodilatory and pulmonary anti‐inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors

  2010cites this paper
• Themed Section: Analytical Receptor Pharmacology in Drug Discovery

  2010cites this paper
• Conformational study of vasoactive intestinal peptide by computational methods.

  2009cites this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery

  2009cites this paper
• Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide.

  2009cites this paper
• VPAC and PAC receptors: From ligands to function.

  2009cites this paper
• Pituitary adenylate cyclase-activating polypeptide

  2009cites this paper
• Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications

  2008influential citation
• Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders

  2008cites this paper
• Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line.

  2008cites this paper
• Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.

  2008cites this paper
• Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.

  2007cites this paper
• Radiosynthesis of 18F-(R8,15,21, L17)-vasoactive intestinal peptide and preliminary evaluation in mice bearing C26 colorectal tumours

  2007cites this paper
• Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy

  2007cites this paper
• A molecular model for intercellular synchronization in the mammalian circadian clock.

  2007influential citation
• Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?

  2007cites this paper
• Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer.

  2007cites this paper
• The pharmacology and function of central VPAC/PAC receptors

  2007cites this paper
• Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.

  2007cites this paper
• GABA and Gi/o differentially control circadian rhythms and synchrony in clock neurons

  2006cites this paper
• Radiolabeling and in vitro and in vivo Characterization of [18F]FB‐[R8,15,21, L17]‐VIP as a PET Imaging Agent for Tumor Overexpressed VIP Receptors

  2006cites this paper
• Location and Function of VPAC1, VPAC2 and NPR-C Receptors in VIP-Induced Vasodilation of Porcine Basilar Arteries

  2006cites this paper
• VIP and PACAP as Autocrine Growth Factors in Breast and Lung Cancer

  2006cites this paper
• Development of Simplified Vasoactive Intestinal Peptide Analogs with Receptor Selectivity and Stability for Human Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-Activating Polypeptide Receptors

  2005cites this paper
• Liposomal vasoactive intestinal peptide.

  2005cites this paper
• Bioactive peptides and proteins in disease

  2004cites this paper
• Generation of Highly Selective VPAC2 Receptor Agonists by High Throughput Mutagenesis of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Peptide*

  2003cites this paper
• Efficient expression of isotopically labeled peptides for high resolution NMR studies: Application to the Cdc42/Rac binding domains of virulent kinases in Candida albicans*

  2003cites this paper
• Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma

  2003cites this paper
• Neuropeptides as autocrine growth factors in cancer cells.

  2003cites this paper
• VIP and drug design.

  2003cites this paper
• VIP as a trophic factor in the CNS and cancer cells.

  2003cites this paper
• Development of Selective Ligands for Pac1, Vpac1 and Vpac2 Receptors

  2003cites this paper
• Function of PACAP in the Respiratory System

  2003cites this paper
• Carbocyanin-markierte Derivate des vasoaktiven intestinalen Peptids fü die Tumordiagnostik

  2002cites this paper
• Assessment of the Bioactive Conformation of the Vasoactive Intestinal Peptide by Computational Methods

  2002cites this paper
• A complete substitutional analysis of VIP for better tumor imaging properties

  2002cites this paper
• Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig.

  2002influential citation
• (N-stearyl, norleucine17) VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist

  2002cites this paper
• The effect of the vasoactive intestinal polypeptide agonist Ro 25–1553 on induced tone in isolated human airways and pulmonary artery

  2001cites this paper
• Parathyroid hormone: an anabolic treatment for osteoporosis.

  2001cites this paper
• The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats

  2001cites this paper
• Bronchodilating properties of the VIP receptor agonist Ro 25-1553 compared to those of formoterol on the guinea-pig isolated trachea.

  2001cites this paper
• Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

  2000cites this paper
• Biodistribution of liposomal 131I-VIP in rat using gamma camera.

  2000cites this paper
• Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.

  2000cites this paper
• Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.

  1999cites this paper
• Pharmaceutical VIP: prospects and problems.

  1999cites this paper
• Biodistribution of liposomal 131I-VIP in rat using gamma camera

  1999cites this paper
• PACAPs-potential for bronchodilation.

  1999cites this paper
• Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.

  1998cites this paper
• Molecular mapping of epitopes involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secretin receptor

  1998cites this paper
• Comparison of the Abilities of Human Parathyroid Hormone (hPTH)-(1-34) and [Leu27]-cyclo(Glu22-Lys26)-hPTH-(1-31)NH2 to Stimulate Femoral Trabecular Bone Growth in Ovariectomized Rats

  1998influential citation
• Stabilization of Vasoactive Intestinal Peptide by Lipids 1

  1998cites this paper
• A novel long-acting VIP analog in the guinea pig trachea in vitro.

  1998cites this paper
• Stabilization of vasoactive intestinal peptide by lipids.

  1998cites this paper
• Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.

  1997cites this paper
• Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neutral endopeptidase EC 3.4.24.11.

  1997cites this paper
• Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region.

  1997cites this paper
• Cyclization by a Specific Lactam Increases the Ability of Human Parathyroid Hormone (hPTH)‐(1–31)NH2 to Stimulate Bone Growth in Ovariectomized Rats

  1997cites this paper
• [Lysine residue as an amino acid substitute for conformational constraint of Xaa-Asp fragment of biologically active peptides using side chain lactamization].

  1997cites this paper
• Therapeutic peptides and peptidomimetics.

  1997cites this paper
• Development of VIP Agonists and Antagonists with Tissue and Receptor Specificity: Effects on Behavioral Maturation, Sexual Function, and the Biologic Clock a

  1996cites this paper
• Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes.

  1996cites this paper